Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

BackgroundPoor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnosed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xueying Liu, Jingxiao Xu, Lixin Bi, Peihao Liu, Xue Jiao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	growth hormone poor ovarian response POSEIDON criteria pregnancy outcome in vitro fertilization Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/d631cf4961294629afa10a2e514d77a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d631cf4961294629afa10a2e514d77a6
record_format	dspace
spelling	oai:doaj.org-article:d631cf4961294629afa10a2e514d77a62021-12-03T09:17:31ZGrowth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria1664-239210.3389/fendo.2021.790160https://doaj.org/article/d631cf4961294629afa10a2e514d77a62021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.790160/fullhttps://doaj.org/toc/1664-2392BackgroundPoor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnosed and stratified by the POSEIDON criteria remains indistinct.MethodsThis retrospective study was performed among women with POR according to the POSEIDON criteria who failed a previous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle, and the subsequent cycle was under GH cotreatment and conducted within 12 months. These participants were stratified into four groups according to the POSEIDON criteria. The comparison was implemented between the failed cycle and the cycle treated with GH. Generalized estimating equation (GEE) multivariate regression was applied for data analysis.ResultsA total of 428 low-prognosis women were included in this study. GH supplementation improved the live birth rates (47.66%, 28.33%, 45.45%, and 24.07%; in groups 1, 2, 3, and 4, respectively) and the clinical pregnancy rates (OR 19.16, 95% CI 7.87–46.63, p < 0.001; OR 7.44, 95% CI 1.65–33.55, p = 0.009; OR 10.19, 95% CI 2.39–43.52, p = 0.002; OR 27.63, 95% CI 4.46–171.11, p < 0.001; in groups 1, 2, 3, and 4, respectively) in all four POSEIDON groups. The number of oocytes retrieved was significantly elevated in the subgroups with normal ovarian reserve (IRR 1.47, 95% CI 1.36–1.59, p < 0.001; IRR 1.31, 95% CI 1.15–1.49, p < 0.001; in groups 1 and 2, respectively). The number of day-3 good-quality embryos was significantly elevated in the subgroups with either normal ovarian reserve or aged young (IRR 2.13, 95% CI 1.78–2.56, p < 0.001; IRR 1.54, 95% CI 1.26–1.89, p < 0.001; IRR 1.47, 95% CI 1.10–1.98, p = 0.010; in groups 1, 2, and 3, respectively).ConclusionGrowth hormone cotreatment could ameliorate the pregnancy outcome for women with POR under the POSEIDON criteria who failed a previous IVF/ICSI cycle. The application of growth hormone for low-prognosis women who experienced a failed cycle might be considered and further studied.Xueying LiuXueying LiuXueying LiuXueying LiuXueying LiuJingxiao XuJingxiao XuJingxiao XuJingxiao XuJingxiao XuLixin BiLixin BiLixin BiLixin BiLixin BiPeihao LiuPeihao LiuPeihao LiuPeihao LiuPeihao LiuXue JiaoXue JiaoXue JiaoXue JiaoXue JiaoFrontiers Media S.A.articlegrowth hormonepoor ovarian responsePOSEIDON criteriapregnancy outcomein vitro fertilizationDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	growth hormone poor ovarian response POSEIDON criteria pregnancy outcome in vitro fertilization Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	growth hormone poor ovarian response POSEIDON criteria pregnancy outcome in vitro fertilization Diseases of the endocrine glands. Clinical endocrinology RC648-665 Xueying Liu Xueying Liu Xueying Liu Xueying Liu Xueying Liu Jingxiao Xu Jingxiao Xu Jingxiao Xu Jingxiao Xu Jingxiao Xu Lixin Bi Lixin Bi Lixin Bi Lixin Bi Lixin Bi Peihao Liu Peihao Liu Peihao Liu Peihao Liu Peihao Liu Xue Jiao Xue Jiao Xue Jiao Xue Jiao Xue Jiao Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
description	BackgroundPoor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnosed and stratified by the POSEIDON criteria remains indistinct.MethodsThis retrospective study was performed among women with POR according to the POSEIDON criteria who failed a previous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle, and the subsequent cycle was under GH cotreatment and conducted within 12 months. These participants were stratified into four groups according to the POSEIDON criteria. The comparison was implemented between the failed cycle and the cycle treated with GH. Generalized estimating equation (GEE) multivariate regression was applied for data analysis.ResultsA total of 428 low-prognosis women were included in this study. GH supplementation improved the live birth rates (47.66%, 28.33%, 45.45%, and 24.07%; in groups 1, 2, 3, and 4, respectively) and the clinical pregnancy rates (OR 19.16, 95% CI 7.87–46.63, p < 0.001; OR 7.44, 95% CI 1.65–33.55, p = 0.009; OR 10.19, 95% CI 2.39–43.52, p = 0.002; OR 27.63, 95% CI 4.46–171.11, p < 0.001; in groups 1, 2, 3, and 4, respectively) in all four POSEIDON groups. The number of oocytes retrieved was significantly elevated in the subgroups with normal ovarian reserve (IRR 1.47, 95% CI 1.36–1.59, p < 0.001; IRR 1.31, 95% CI 1.15–1.49, p < 0.001; in groups 1 and 2, respectively). The number of day-3 good-quality embryos was significantly elevated in the subgroups with either normal ovarian reserve or aged young (IRR 2.13, 95% CI 1.78–2.56, p < 0.001; IRR 1.54, 95% CI 1.26–1.89, p < 0.001; IRR 1.47, 95% CI 1.10–1.98, p = 0.010; in groups 1, 2, and 3, respectively).ConclusionGrowth hormone cotreatment could ameliorate the pregnancy outcome for women with POR under the POSEIDON criteria who failed a previous IVF/ICSI cycle. The application of growth hormone for low-prognosis women who experienced a failed cycle might be considered and further studied.
format	article
author	Xueying Liu Xueying Liu Xueying Liu Xueying Liu Xueying Liu Jingxiao Xu Jingxiao Xu Jingxiao Xu Jingxiao Xu Jingxiao Xu Lixin Bi Lixin Bi Lixin Bi Lixin Bi Lixin Bi Peihao Liu Peihao Liu Peihao Liu Peihao Liu Peihao Liu Xue Jiao Xue Jiao Xue Jiao Xue Jiao Xue Jiao
author_facet	Xueying Liu Xueying Liu Xueying Liu Xueying Liu Xueying Liu Jingxiao Xu Jingxiao Xu Jingxiao Xu Jingxiao Xu Jingxiao Xu Lixin Bi Lixin Bi Lixin Bi Lixin Bi Lixin Bi Peihao Liu Peihao Liu Peihao Liu Peihao Liu Peihao Liu Xue Jiao Xue Jiao Xue Jiao Xue Jiao Xue Jiao
author_sort	Xueying Liu
title	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
title_short	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
title_full	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
title_fullStr	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
title_full_unstemmed	Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
title_sort	growth hormone cotreatment for low-prognosis patients according to the poseidon criteria
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d631cf4961294629afa10a2e514d77a6
work_keys_str_mv	AT xueyingliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xueyingliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xueyingliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xueyingliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xueyingliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT jingxiaoxu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT jingxiaoxu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT jingxiaoxu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT jingxiaoxu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT jingxiaoxu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT lixinbi growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT lixinbi growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT lixinbi growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT lixinbi growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT lixinbi growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT peihaoliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT peihaoliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT peihaoliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT peihaoliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT peihaoliu growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xuejiao growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xuejiao growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xuejiao growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xuejiao growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria AT xuejiao growthhormonecotreatmentforlowprognosispatientsaccordingtotheposeidoncriteria
_version_	1718373360433364992

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

Ejemplares similares